Joanne Wuensch
Stock Analyst at Citigroup
(4.40)
# 358
Out of 5,133 analysts
441
Total ratings
65.98%
Success rate
12.02%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $98 → $94 | $88.34 | +6.41% | 23 | Dec 11, 2025 | |
| SYK Stryker | Maintains: Buy | $455 → $420 | $355.82 | +18.04% | 15 | Dec 11, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $5.5 → $9.1 | $6.83 | +33.24% | 14 | Dec 11, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $215 → $232 | $213.65 | +8.59% | 16 | Dec 11, 2025 | |
| ITGR Integer Holdings | Maintains: Neutral | $69 → $75 | $82.74 | -9.35% | 9 | Dec 11, 2025 | |
| GKOS Glaukos | Maintains: Buy | $113 → $125 | $110.23 | +13.40% | 23 | Dec 11, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Neutral | $83 → $88 | $84.77 | +3.81% | 8 | Dec 11, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Neutral | $62 → $75 | $65.13 | +15.15% | 8 | Dec 11, 2025 | |
| EW Edwards Lifesciences | Maintains: Buy | $96 → $101 | $83.84 | +20.47% | 22 | Dec 11, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $16 → $22 | $20.90 | +5.26% | 21 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $77 | $70.25 | +9.61% | 17 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $285 → $350 | $300.97 | +16.29% | 26 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $650 → $635 | $561.82 | +13.03% | 18 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $77 → $88 | $78.82 | +11.65% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $88 | $81.70 | +7.71% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $11 | $12.34 | -10.86% | 16 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $21 | $19.65 | +6.87% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $205 → $242 | $155.44 | +55.69% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $112 | $96.42 | +16.16% | 22 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $155 | $124.30 | +24.70% | 22 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $17.45 | -14.04% | 6 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $4.15 | $1.95 | +112.82% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $380 | $278.17 | +36.61% | 16 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $119 → $125 | $94.14 | +32.78% | 35 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $201.52 | +24.06% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $78.99 | -12.65% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $254.67 | -50.13% | 6 | Dec 10, 2018 |
Zimmer Biomet Holdings
Dec 11, 2025
Maintains: Neutral
Price Target: $98 → $94
Current: $88.34
Upside: +6.41%
Stryker
Dec 11, 2025
Maintains: Buy
Price Target: $455 → $420
Current: $355.82
Upside: +18.04%
Sight Sciences
Dec 11, 2025
Maintains: Neutral
Price Target: $5.5 → $9.1
Current: $6.83
Upside: +33.24%
Johnson & Johnson
Dec 11, 2025
Maintains: Buy
Price Target: $215 → $232
Current: $213.65
Upside: +8.59%
Integer Holdings
Dec 11, 2025
Maintains: Neutral
Price Target: $69 → $75
Current: $82.74
Upside: -9.35%
Glaukos
Dec 11, 2025
Maintains: Buy
Price Target: $113 → $125
Current: $110.23
Upside: +13.40%
GE HealthCare Technologies
Dec 11, 2025
Maintains: Neutral
Price Target: $83 → $88
Current: $84.77
Upside: +3.81%
Establishment Labs Holdings
Dec 11, 2025
Maintains: Neutral
Price Target: $62 → $75
Current: $65.13
Upside: +15.15%
Edwards Lifesciences
Dec 11, 2025
Maintains: Buy
Price Target: $96 → $101
Current: $83.84
Upside: +20.47%
Tandem Diabetes Care
Dec 11, 2025
Maintains: Neutral
Price Target: $16 → $22
Current: $20.90
Upside: +5.26%
Dec 11, 2025
Maintains: Buy
Price Target: $75 → $77
Current: $70.25
Upside: +9.61%
Dec 11, 2025
Upgrades: Buy
Price Target: $285 → $350
Current: $300.97
Upside: +16.29%
Dec 11, 2025
Downgrades: Neutral
Price Target: $650 → $635
Current: $561.82
Upside: +13.03%
Dec 11, 2025
Downgrades: Neutral
Price Target: $77 → $88
Current: $78.82
Upside: +11.65%
Dec 8, 2025
Maintains: Neutral
Price Target: $72 → $88
Current: $81.70
Upside: +7.71%
Oct 31, 2025
Maintains: Sell
Price Target: $12 → $11
Current: $12.34
Upside: -10.86%
Oct 31, 2025
Maintains: Neutral
Price Target: $26 → $21
Current: $19.65
Upside: +6.87%
Oct 31, 2025
Maintains: Buy
Price Target: $205 → $242
Current: $155.44
Upside: +55.69%
Oct 7, 2025
Maintains: Buy
Price Target: $101 → $112
Current: $96.42
Upside: +16.16%
Jul 18, 2025
Maintains: Buy
Price Target: $157 → $155
Current: $124.30
Upside: +24.70%
Jul 9, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $17.45
Upside: -14.04%
May 22, 2025
Maintains: Neutral
Price Target: $6.5 → $4.15
Current: $1.95
Upside: +112.82%
May 22, 2025
Maintains: Buy
Price Target: $320 → $380
Current: $278.17
Upside: +36.61%
May 22, 2025
Maintains: Buy
Price Target: $119 → $125
Current: $94.14
Upside: +32.78%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $201.52
Upside: +24.06%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $78.99
Upside: -12.65%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $254.67
Upside: -50.13%